Invivyd's VMS063 shows potent activity against measles variants in lab tests
IVVD•Invivyd presented preclinical data showing its investigational measles antibody VMS063 had potent laboratory antiviral activity against historical and contemporary variants, including B3 and D8. Manufacturing scale-up has begun toward clinical development in 2027.
1. Preclinical measles data
Invivyd presented preclinical data at IDWeek 2026 showing potent laboratory antiviral activity for its investigational measles antibody VMS063. Tests covered historical and contemporary variants, including B3 and D8, supporting potential use for treatment and prevention.
2. Development plans
Manufacturing scale-up has begun toward clinical development in 2027, with intramuscular or subcutaneous formulations planned. No FDA-approved measles treatments currently exist.
